Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies

Autor: Shiying Hao, Xuefeng B. Ling, Shan X. Wang, Jung Rok Lee, Lingyun Xu, Sanjiv S. Gambhir, James D. Brooks
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Physiology
Antibodies
Neoplasm
Biochemistry
Prostate cancer
0302 clinical medicine
Immune Physiology
Medicine and Health Sciences
Nanotechnology
Multiplex
Bradford protein assay
Immunoassay
Multidisciplinary
Immune System Proteins
medicine.diagnostic_test
Prostate Cancer
Area under the curve
Prostate Diseases
Middle Aged
Recombinant Proteins
3. Good health
Oncology
030220 oncology & carcinogenesis
Medicine
Engineering and Technology
Kallikreins
Research Article
Science
Urology
Immunology
Research and Analysis Methods
Sensitivity and Specificity
Antibodies
03 medical and health sciences
Diagnostic Medicine
medicine
Protein Concentration Assays
Cancer Detection and Diagnosis
Humans
Molecular Biology Techniques
Molecular Biology
Autoantibodies
Aged
Molecular Biology Assays and Analysis Techniques
business.industry
Autoantibody
PARK7
Cancer
Biology and Life Sciences
Proteins
Cancers and Neoplasms
Prostatic Neoplasms
Prostate-Specific Antigen
medicine.disease
Monoclonal Antibodies
Genitourinary Tract Tumors
030104 developmental biology
Cancer research
Nanoparticles
business
Biomarkers
Zdroj: PLoS ONE
PLoS ONE, Vol 14, Iss 8, p e0221051 (2019)
ISSN: 1932-6203
Popis: PurposeTo develop a magneto-nanosensor (MNS) based multiplex assay to measure protein and autoantibody biomarkers from human serum for prostate cancer (CaP) diagnosis.Materials and methodsA 4-panel MNS autoantibody assay and a MNS protein assay were developed and optimized in our labs. Using these assays, serum concentration of six biomarkers including prostate-specific antigen (PSA) protein, free/total PSA ratio, as well as four autoantibodies against Parkinson disease 7 (PARK7), TAR DNA-binding protein 43 (TARDBP), Talin 1 (TLN1), and Caldesmon 1 (CALD1) and were analyzed. Human serum samples from 99 patients (50 with non-cancer and 49 with clinically localized CaP) were evaluated.ResultsThe MNS assay showed excellent performance characteristics and no cross-reactivity. All autoantibody assays showed a statistically significant difference between CaP and non-cancer samples except for PARK7. The most significant difference was the combination of the four autoantibodies as a panel in addition to the free/total PSA ratio. This combination had the highest area under the curve (AUC)- 0.916 in ROC analysis.ConclusionsOur results suggest that this autoantibody panel along with PSA and free PSA have potential to segregate patients without cancer from those with prostate cancer with higher sensitivity and specificity than PSA alone.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje